Novartis' novel heart drug, formerly called LCZ696, was given a huge boost when experts from the American College of Cardiology, the American Heart Association and the European Society of Cardiology on May 21 announced that Entresto (valsartan/sacubitril) should replace old ACE inhibitors and ARBs in patients with adequate blood pressure and drug tolerance.
In the US, the twice-a-day medicine is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) as...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
